These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 21679008)

  • 21. Therapeutic benefits and safety of carvedilol in the treatment of renal hypertension. An open, short term study. Carvedilol Renal Hypertension Study Group in Japan.
    Kohno M; Takeda T; Ishii M; Saruta T; Mizuno Y; Yoshimura M; Kubo S; Fukiyama K; Fujishima M
    Drugs; 1988; 36 Suppl 6():129-35. PubMed ID: 2908299
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of carvedilol in hypertension: an update.
    Leonetti G; Egan CG
    Vasc Health Risk Manag; 2012; 8():307-22. PubMed ID: 22661898
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of carvedilol in comparison with atenolol in hypertensive patients pretreated with hydrochlorothiazide.
    van der Does R; Widmann L; Uberbacher HJ; Hörrmann M; Machwirth M; Stienen U
    Eur J Clin Pharmacol; 1990; 38 Suppl 2():S147-52. PubMed ID: 1974506
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Surveillance on The Safety and Efficacy of Ambrisentan (Volibris Tablet 2.5 mg) in Patients with Pulmonary Arterial Hypertension in Real Clinical Practice: Post-marketing Surveillance (Interim Analysis Report).
    Takahashi T; Hayata S; Kobayashi A; Onaka Y; Ebihara T; Hara T
    Clin Drug Investig; 2018 Mar; 38(3):219-229. PubMed ID: 29282676
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics and efficacy of carvedilol in hypertensive patients with chronic renal failure and hemodialysis patients.
    Masumura H; Miki S; Kaifu Y; Kitajima W; Abe Y
    J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S102-7. PubMed ID: 1378134
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antihypertensive treatment with a vasodilating beta-blocker, carvedilol, in chronic hemodialysis patients.
    Deetjen A; Heidland A; Pangerl A; Meyer-Sabellek W; Schaefer RM
    Clin Nephrol; 1995 Jan; 43(1):47-52. PubMed ID: 7697935
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term efficacy and tolerability of a fixed-dose combination of antihypertensive agents: an open-label surveillance study in China.
    Wu Y; Hu Y; Tang X; He L; Ren T; Tao Q; Qin X; Sun N; Wang H; Cao W; Wu T; Zhan S; Wang J; Chen W; Li L
    Clin Drug Investig; 2011 Nov; 31(11):769-77. PubMed ID: 21671689
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BP goal achievement in patients with uncontrolled hypertension : results of the treat-to-target post-marketing survey with irbesartan.
    Schrader J; Bramlage P; Lüders S; Thoenes M; Schirmer A; Paar DW
    Clin Drug Investig; 2007; 27(11):783-96. PubMed ID: 17914897
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term safety and treatment outcomes of pegvisomant in Japanese patients with acromegaly: results from the post-marketing surveillance.
    Yamaguchi H; Shimatsu A; Okayama A; Sato T
    Endocr J; 2020 Feb; 67(2):201-210. PubMed ID: 31723069
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Positive association between baseline brachial-ankle pulse wave velocity and the risk of new-onset diabetes in hypertensive patients.
    Zhang Y; He P; Li Y; Zhang Y; Li J; Liang M; Wang G; Tang G; Song Y; Wang B; Liu C; Liu L; Cui Y; Wang X; Huo Y; Xu X; Qin X
    Cardiovasc Diabetol; 2019 Aug; 18(1):111. PubMed ID: 31462258
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term safety, tolerability, and antihypertensive efficacy of aliskiren, an oral direct renin inhibitor, in Japanese patients with hypertension.
    Kushiro T; Itakura H; Abo Y; Gotou H; Terao S; Keefe DL
    Hypertens Res; 2009 Mar; 32(3):169-75. PubMed ID: 19262478
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of carvedilol in elderly hypertensive patients.
    Morgan TO; Anderson A; Cripps J; Adam W
    Eur J Clin Pharmacol; 1990; 38 Suppl 2():S129-33. PubMed ID: 1974503
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety of the coadministration of carvedilol and nifedipine sustained-release in the treatment of essential hypertension.
    Juttmann JR; de Vries Robles P; Venuti RP
    J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S134-7. PubMed ID: 1378141
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the hemodynamic effects of metoprolol and carvedilol in hypertensive patients.
    Weber K; Bohmeke T; van der Does R; Taylor SH
    Cardiovasc Drugs Ther; 1996 May; 10(2):113-7. PubMed ID: 8842502
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials.
    Liu J; Pong A; Gallo S; Darekar A; Terra SG
    Cardiovasc Diabetol; 2019 May; 18(1):59. PubMed ID: 31064361
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of long-term losartan therapy demonstrated by a prospective observational study in Japanese patients with hypertension: The Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study.
    Naritomi H; Fujita T; Ito S; Ogihara T; Shimada K; Shimamoto K; Tanaka H; Yoshiike N
    Hypertens Res; 2008 Feb; 31(2):295-304. PubMed ID: 18360050
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Olmesartan medoxomil in elderly patients with essential or isolated systolic hypertension : efficacy and safety data from clinical trials.
    Heagerty AM; Mallion JM
    Drugs Aging; 2009; 26(1):61-76. PubMed ID: 19102515
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the antihypertensive effects of carvedilol and metoprolol on resting and exercise blood pressure.
    Franz IW; Agrawal B; Wiewel D; Ketelhut R
    Clin Investig; 1992; 70 Suppl 1():S53-7. PubMed ID: 1350485
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness and tolerability of fixed-dose combination enalapril plus nitrendipine in hypertensive patients: results of the 3-month observational, post-marketing, multicentre, prospective CENIT study.
    Sierra A; Roca-Cusachs A; Redón J; Marín R; Luque M; Figuera M; Garcia-Garcia M; Falkon L
    Clin Drug Investig; 2009; 29(7):459-469. PubMed ID: 19499963
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of once-daily carvedilol vs twice-daily labetalol in mild to moderate hypertension.
    Ollivier JP; Durier P; Bussiere JL; Gayet JL
    Eur J Clin Pharmacol; 1990; 38 Suppl 2():S164-6. PubMed ID: 1974509
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.